Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-08-31 , DOI: 10.1111/dom.14534
Søren S. Lund ₁ , Naveed Sattar ₂ , Afshin Salsali ₃ , Dietmar Neubacher ₄ , Henry N. Ginsberg ₅

Affiliation

To examine the association between changes in lipids and markers of haemoconcentration (haematocrit and serum albumin) with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes (T2D) using pooled data from four phase 3 randomized trials.

中文翻译：

血液浓度对 2 型糖尿病患者使用恩格列净脂质变量变化的潜在贡献：对来自四项 3 期随机临床试验的汇总数据的事后分析

使用来自四项 3 期随机试验的汇总数据，在 2 型糖尿病 (T2D) 患者中使用恩格列净（一种钠-葡萄糖协同转运蛋白 2 抑制剂）检查血脂变化与血浓度标志物（血细胞比容和血清白蛋白）之间的关联.

更新日期：2021-11-08

点击分享查看原文

点击收藏

阅读更多本刊最新论文